Does amifostine have radioprotective effects on salivary glands in high-dose radioactive iodine-treated differentiated thyroid cancer

European Journal of Nuclear Medicine and Molecular Imaging

Volumn 37, Issue 9, 2010, Pages 1778-1785

  Ma, Chao ^a   Xie, Jiawei ^a   Jiang, Zhongxin ^a   Wang, Guoming ^a   Zuo, Shuyao ^a  

^a QINGDAO UNIVERSITY   (China)

Author keywords

Amifostine; Iodine 131; Salivary gland

Indexed keywords

AMIFOSTINE; IODINE 131; PERTECHNETIC ACID TC 99M; PLACEBO;

BLOOD PRESSURE; CANCER RADIOTHERAPY; CHILL; CLINICAL TRIAL; DRUG EFFECT; DRUG MEGADOSE; FEVER; FLUSHING; HUMAN; HYPOCALCEMIA; HYPOTENSION; MALAISE; RADIATION PROTECTION; RADIOISOTOPE THERAPY; RASH; REVIEW; SALIVARY GLAND DISEASE; SALIVATION; SIDE EFFECT; SNEEZING; SOMNOLENCE; TASTE DISORDER; THYROID CANCER; TREATMENT OUTCOME; VOMITING; XEROSTOMIA;

AMIFOSTINE; ANIMALS; HUMANS; IODINE RADIOISOTOPES; RADIATION DOSAGE; RADIATION-PROTECTIVE AGENTS; SALIVARY GLANDS; THYROID NEOPLASMS;

EID: 77956192330     PISSN: 16197070     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00259-009-1368-6     Document Type: Review

References (51)

1. BK Edwards HL Howe LA Ries MJ Thun HM Rosenberg R Yancik, et al. 2002 Annual report to the nation on the status of cancer, 1973-1999, featuring implications of age and aging on the U.S. cancer burden Cancer 94 2766 2792 10.1002/cncr.10593 12173348
2. L Wartofsky 2002 rhTSH-Stimulated thyroglobulin study group techniques in thyroidology: management of low-risk well-differentiated thyroid cancer based only on thyroglobulin measurement after recombinant human thyrotropin Thyroid 12 583 589 10.1089/105072502320288438 1:CAS:528:DC%2BD38XmsFaqt7Y%3D 12193302
3. AM Sawka K Thephamongkhol M Brouwers L Thabane G Browman HC Gerstein 2004 A systematic review and meta-analysis of the effectiveness of radioactive iodine remnant ablation for well-differentiated thyroid cancer J Clin Endocrinol Metab 89 3668 3676 10.1210/jc.2003-031167 1:CAS:528:DC%2BD2cXmslKmsbc%3D 15292285
4. E Hindié P Zanotti-Fregonara F Duron I Keller P Bouchard JY Devaux 2007 Should 'low-risk' thyroid cancer patients with residual thyroglobulin be re-treated with iodine 131? Clin Endocrinol (Oxf) 66 3 329 334 10.1111/j.1365-2265.2006.02731.x
5. EL Mazzaferri 2007 Management of low-risk differentiated thyroid cancer Endocr Pract 13 5 498 512 17872353
6. KH Bohuslavizki W Brenner H Wolf C Sippel G Toenshoff S Tinnemeyer, et al. 1995 Value of quantitative salivary gland scintigraphy in the early stage of Sjögren's syndrome Nucl Med Commun 16 917 922 10.1097/00006231-199511000- 00007 1:STN:280:DyaK287lsFSjtQ%3D%3D 8587757
7. KH Bohuslavizki W Brenner S Lassmann S Tinnemeyer G Toenshoff C Sippel, et al. 1996 Quantitative salivary gland scintigraphy in the diagnosis of parenchymal damage after treatment with radioiodine Nucl Med Commun 17 681 686 10.1097/00006231-199608000-00006 1:STN:280:DyaK2s%2Fjt1agsw%3D%3D 8878127
8. KH Bohuslavizki W Brenner S Lassmann S Tinnemeyer S Kalina M Clausen, et al. 1997 Quantitative salivary gland scintigraphy - a recommended examination prior to and after radioiodine therapy Nuklearmedizin 36 103 109 1:STN:280:DyaK2s3ntlChug%3D%3D 9162904
9. MA Walter CP Turtschi C Schindler P Minnig J Müller-Brand B Müller 2007 The dental safety profile of high-dose radioiodine therapy for thyroid cancer: long-term results of a longitudinal cohort study J Nucl Med 48 10 1620 1625 10.2967/jnumed.107.042192 17873131
10. Clarke SEM. Radioiodine therapy of the thyroid. In: MurrayI PC, ElI PJ, editors. Nuclear medicine in clinical diagnosis and therapy. Edinburgh: Churchill Livingstone; 1994. p. 833-45.
11. C Spitzweg W Joba K Schriever JR Goellner JC Morris AE Heufelder 1999 Analysis of human sodium iodide symporter immunoreactivity in human exocrine glands J Clin Endocrinol Metab 84 4178 4184 10.1210/jc.84.11.4178 1:CAS:528:DyaK1MXntlOqu7c%3D 10566669
12. P Allweiss GD Braunstein A Katz A Waxman 1984 Sialadenitis following I-131 therapy for thyroid carcinoma: concise communication J Nucl Med 25 755 758 1:STN:280:DyaL2c3kt1Sisg%3D%3D 6737074
13. KH Bohuslavizki W Brenner S Klutmann RH Hubner S Lassmann B Feyerabend, et al. 1998 Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy J Nucl Med 39 1237 1242 1:CAS:528:DyaK1cXkvVWltrg%3D 9669401
14. KH Bohuslavizki S Klutmann W Brenner J Mester E Henze M Clausen 1998 Salivary gland protection in high-dose radioiodine treatment: results of a double blind placebo-controlled study J Clin Oncol 16 3542 3549 1:CAS:528:DyaK1cXnsVOgtrY%3D 9817273
15. J Cohen 1960 A coefficient of agreement for nominal scales Educ Psychol Measur 20 37 46 10.1177/001316446002000104
16. Higgins JPT, Green S, editors. Cochrane handbook for systematic reviews of interventions version 5.0.0. The Cochrane Collaboration. www.cochrane- handbook.org. 2008.
17. JPT Higgins SG Thompson JJ Deeks DG Altman 2003 Measuring inconsistency in meta-analysis BMJ 327 557 560 10.1136/bmj.327.7414.557 12958120
18. SJ Kim HY Choi IJ Kim YK Kim S Jun HY Nam, et al. 2008 Limited cytoprotective effects of amifostine in high-dose radioactive iodine 131-treated well-differentiated thyroid cancer patients: analysis of quantitative salivary scan Thyroid 18 325 331 10.1089/thy.2007.0191 1:CAS:528:DC%2BD1cXjt1Gju7k%3D 18341378
19. KH Bohuslavizki S Klutmann W Brenner S Kroger R Buchert C Bleckmann, et al. 1999 Radioprotection of salivary glands by amifostine in high-dose radioiodine treatment Strahlenther Onkol 175 Suppl 4 6 12 10584133
20. KH Bohuslavizki S Klutmann C Bleckmann W Brenner S Lassmann J Mester, et al. 1999 Salivary gland protection by amifostine in high-dose radioiodine therapy of differentiated thyroid cancer Strahlenther Onkol 175 57 61 10.1007/BF02753843 1:STN:280:DyaK1M7msVGgsQ%3D%3D 10065139
21. O Levy A Vieja N Carrasco 1998 The Na+I- symporter (NIS): recent advances J Bioenerg Biomembr 30 195 206 10.1023/A:1020577426732 1:CAS:528: DyaK1cXkt1Onu7c%3D 9672241
22. PA Smanik Q Liu TL Furminger K Ryu S Xing EL Mazzaferri, et al. 1996 Cloning of the human sodium iodide symporter Biochem Biophys Res Commun 226 339 345 10.1006/bbrc.1996.1358 1:CAS:528:DyaK28Xls1yis7g%3D 8806637
23. C Spitzweg AE Heufelder 1998 The sodium iodide symporter: its emerging relevance to clinical endocrinology Eur J Endocrinol 138 374 375 10.1530/eje.0.1380374 1:CAS:528:DyaK1cXjsFSru74%3D 9578502
24. JK Chung 2002 Sodium iodide symporter: its role in nuclear medicine J Nucl Med 43 1188 1200 1:CAS:528:DC%2BD38Xns1elsro%3D 12215558
25. HH Albrecht H Creutzig 1976 Salivary gland scintigraphy after radio-iodine therapy. Functional scintigraphy of the salivary gland after high dose radio-iodine therapy Nuklearmedizin 125 546 553 1:STN:280: DyaE2s%2Fpt1GltQ%3D%3D
26. BJ Baum 1993 Principles of saliva secretion Ann N Y Acad Sci 694 17 23 10.1111/j.1749-6632.1993.tb18338.x 1:CAS:528:DyaK3sXms1amurY%3D 8105741
27. J Helman RJ Turner PC Fox BJ Baum 1987 99mTc-pertechnetate uptake in parotid acinar cells by the Na+/K+/Cl- co-transport system J Clin Invest 79 1310 1313 10.1172/JCI112954 1:CAS:528:DyaL2sXktlGksbY%3D 3033020
28. GA Gates WP Work 1967 Radioisotope scanning of the salivary glands Laryngoscope 77 861 875 10.1288/00005537-196705000-00013 1:STN:280: DyaF2s7msFCrsw%3D%3D 6026278
29. D Levenson S Coulec M Sonnenberg E Lai SJ Goldsmith SM Larson 1994 Peripheral facial nerve palsy after high-dose radioiodine therapy in patients with papillary thyroid carcinoma Ann Intern Med 120 576 578 1:STN:280: DyaK2c7mtFCisQ%3D%3D 8116996
30. H Maier H Bihl 1987 Effect of radioactive iodine therapy on parotid gland function Acta Otolaryngol 103 318 324 1:STN:280:DyaL2s3gvFSlsw%3D%3D 3495094
31. SJ Mandel L Mandel 2003 Radioactive iodine and the salivary glands Thyroid 13 265 271 10.1089/105072503321582060 1:CAS:528:DC%2BD3sXjtVymtLc%3D 12729475
32. S Dugonji B Ajdinovi D Stefanovi L Jaukovi 2008 Diagnostic validity of dynamic salivary gland scintigraphy with ascorbic acid stimulation in patients with Sjoegren's syndrome: comparison with unstimulated whole sialometry Vojnosanit Pregl 65 41 46
33. RL Cappizi 1999 The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine Semin Oncol 26 3 21
34. HM Patt EB Tyree RL Straube, et al. 1949 Cysteine protection against X irradiation Science 110 213 214 10.1126/science.110.2852.213 1:CAS:528:DyaG3cXnvVA%3D 17811258
35. S McDonald C Meyerowitz T Smudzin, et al. 1994 Preliminary results of a pilot study using WR-272t before fractionated irradiation of the head and neck to reduce salivary gland dysfunction Int J Radiat Oncol Biol Phys 29 747 754 1:STN:280:DyaK2czhsVGqsA%3D%3D 8040020
36. H Niibe I Takahashi N Mitsuhashi, et al. 1985 An evaluation of the clinical usefulness of amifostine (YM-08310) radioprotective agent. A double-blind placebo-controlled study. 1. Head and neck tumor Nippon Gan Chiryo Gakkai Shi 20 984 993 1:STN:280:DyaL28%2FjsFOisw%3D%3D 2997351
37. I Takahashi T Nagai K Miyaishi, et al. 1986 Clinical study of the radioprotective effects of amifostine (YM-083 10. WR-272I ) on chronic radiation injury Int J Radiat Oncol Biol Phys 12 935 938 1:STN:280:DyaL283ltVantQ%3D%3D 3013816
38. JS Rasey Z Grunbaum KA Krohn TW Menard AM Spence 1885 Biodistribution of the radioprotective drug S-labeled 3-amino-2-hydroxypropyl phosphorothioate (WR-77913) Radiat Res 102 130 137 10.2307/3576436
39. JF Utley C Marlowe WJ Waddell 1976 Distribution of 3SS-labeled WR-2721 in normal and malignant tissues of the mouse Radiat Res 68 284 291 10.2307/3574479 1:CAS:528:DyaE2sXotlCntA%3D%3D 185642
40. JF Utley TL Phillips LJ Kane 1976 Protection of normal tissues by WR-2721 during fractionated irradiation AACN Clin Issues 1 699 703 1:CAS:528: DyaE2sXis1Sjtg%3D%3D
41. KH Bohuslavizki S Klutmann L Jenicke S Kröger R Buchert J Mester M Clausen 1999 Salivary gland protection by S-2-(3-aminopropylamino)- ethylphosphorothioic acid (amifostine) in high-dose radioiodine treatment: results obtained in a rabbit animal model and in a double-blind multi-arm trial Cancer Biother Radiopharm 14 5 337 347 10.1089/cbr.1999.14.337 1:CAS:528:DyaK1MXntVOnurk%3D 10850318
42. KH Bohuslavizki S Klutmann L Jenicke W Brenner B Feyerabend E Henze, et al. 1999 Radioprotection of salivary glands by S-2-(3-aminopropylamino)- ethylphosphorothioic (amifostine) obtained in a rabbit animal model Int J Radiat Oncol Biol Phys 45 1 181 186 1:CAS:528:DyaK1MXlslSmurg%3D 10477022
43. C Sagowski S Wenzel L Jenicke KH Bohuslavizki W Kehrl F Zywietz, et al. 2002 Reducing late toxicity with amifostine in fractionated irradiation of the rat salivary glands HNO 50 9 822 828 10.1007/s00106-001-0595-3 1:STN:280:DC%2BD38nmsFeiuw%3D%3D 12425136
44. H Kutta U Kampen C Sagowski W Brenner KH Bohuslavizki F Paulsen 2005 Amifostine is a potent radioprotector of salivary glands in radioiodine therapy. Structural and ultrastructural findings Strahlenther Onkol 181 4 237 245 10.1007/s00066-005-1353-3 15827693
45. S Boehme DB Wilson 2004 Amifostine-induced fever: case report and review of the literature Pharmacotherapy 24 155 158 10.1592/phco.24.1.155.34799 14740795
46. D Rades F Fehlauer A Bajrovic B Mahlmann E Richter W Alberti 2004 Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients Radiother Oncol 70 261 264 10.1016/j.radonc.2003.10.005 1:CAS:528:DC%2BD2cXivVWltr8%3D 15064010
47. AP Brown WP Greening VR McCready HJ Shaw CL Harmer 1984 Radioiodine treatment of metastatic thyroid carcinoma: the Royal Marsden Hospital experience Br J Radiol 57 323 327 10.1259/0007-1285-57-676-323 1:STN:280: DyaL2c7lsFegug%3D%3D 6704664
48. TO Narhi 1994 Prevalence of subjective feelings of dry mouth in the elderly J Dent Res 73 20 25 1:STN:280:DyaK2c7isVOntw%3D%3D 8294614
49. JE Freitas MD Gross S Ripley B Shapiro 1985 Radionuclide diagnosis and therapy of thyroid cancer: current status report Semin Nucl Med 5 106 131 10.1016/S0001-2998(85)80021-0
50. Mazzaferri EL. Carcinoma of the follicular epithelium: radioiodine and other treatment outcomes. In: Braverman LE, Utiger RD, editors. The thyroid: a fundamental and clinical text. Philadelphia: Lippincott Williams & Wilkins; 2000. p. 904-9
51. W Spiegel C Reiners W Borner 1985 Sialadenitis following iodine-131 therapy for thyroid carcinoma J Nucl Med 26 816 817